Abstract
Clinical research in the past decade has been said to confirm the conceptual separation of small cell lung cancer (SCLC) and non-SCLC as distinct clinical entities [1]. As studies have matured, however, a number of their findings suggest that the boundary may be less clear than originally thought. The ‘responsiveness’ to both radiation and drugs has been said to characterize SCLC and yet virtually all patients with extensive disease are dead within 2 years (median survival < 1 year), not dramatically different than patients with extensive non-SCLC, most of whom are dead within one yar (median survival about 0.5 year) [1]. More important, the ability to predict which 25% of patients will get a response (5% CR, 20% PR) in extensive non-SCLC and which 25% of patients with extensive SCLC will have a complete response to therapy is limited to global predictors like performance status, prior weight loss and extent of disease. It is small wonder that most investigators feel we have reached a plateau in our treatment of both SCLC and non-SCLC using routine cytotoxic therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Minna JD, Higgins G A and Glatstein EJ: ‘Cancer of the Lung’. In: Principles and Practice of Oncology, De Vita VT, Hellman S, Rosenberg SA (eds.). J.B. Lippincott, Philadelphia, p 396, 1981.
Gazdar AF, Carney DN, Russell EK et al.: Establishment of continuous, clonable small cell carcinomas of the lung cultures having amine precursor uptake and decarboxylation properties. Cancer Res 40:3502, 1980.
Carney DN, Gazdar AF, Bepler G et al.: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913, 1985.
Gazdar AF, Carney DN, Nau MM et al.: Characterization of variant subclasses of cell lines derived form small cell lung cancer having distinctive biochemical, morphological and growth properties. Cancer Res 45:2924, 1985.
Ettinger DS, Baker RR, Eggleston JC et al.: Prospective evaluation of the role of surgery in limited disease (LD) small cell lung cancer. An ECOG pilot study. Proc. ASCO 4:180, 1985.
Little CD, Nan MM, Carney DN et al.: Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (Lond.) 306:194, 1983.
Warren WH, Memoli VA, Kittle CF et al.: The biological implications of bronchial tumors. J Thor Cardio vase Surg 87:274, 1984.
Gazdar AF, Carney DN, Guccion JG et al.: ‘Small cell carcinoma of the lung: cellular origin and relationship to other pulmonary tumors. In: Small Cell Lung Cancer, Greco A, Bunn PA and Oldham R (eds.), Grune and Stratton, New York, p 145, 1981.
Gazdar AF, Oie H, Russell E et al.: Establishment and characterization of a large comprehensive panel of cell lines demonstrates the diversity of human lung cancer. Proc. AACR 26:27, 1985.
Bunn PA, Carney DN, Gazdar AF et al.: Flow cytometric DNA content analysis in lung cancer: diagnostic and biological implications. Cancer Res 43:5026, 1983.
Brower M, Carney DN, Oie HK et al.: Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res, in press.
Gazdar AF and Oie HK: Cell culture methods for human lung cancer. Cancer Genetics and Cytogenetics, in press.
Barnes D and Sato G: Serum-free cell culture: a unifying approach. Cell 22:649, 1980.
Ervin TJ, Beckett MA, Miller D et al.: Clonal growth and serial passage of head and neck squamous cell carcinoma: tumor site determines cultivability. Proc ASCO 1:195, 1982.
Barnes D, van der Bosch J, Masui H et al.: The culture of human tumor cells in serum-free medium. Methods Enzymol 79:368, 1981.
Simms E, Gazdar AF, Abrams PG et al.: Growth of human small cell (oat cell) carcinoma of the lung in serum-free, growth factor-supplemented medium. Cancer Res 40:4356, 1980.
Ruckdeschel JC, Gazdar AF, Carney DN et al: The use of human cancer cell lines for in vitro chemosensitivity testing. Proc AACR 26:367, 1985.
Baylin SB, Gazdar AF, Minna JD et al.: A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. Proc Nat Acad Sci (USA) 79:4650, 1982.
Cuttitta F, Rosen S, Gazdar AF et al.: Monoclonal antibodies which demonstrate specificity for several types of human lung cancer. Proc Nat Acad Sci (USA) 78:4591, 1981.
Minna JD, Carney DN, Cuttitta F et al: ‘The Biology of Lung Cancer’. In: Rational Basis for Chemotherapy. Alan R Liss, Inc, New York, pl., 1983.
Doyle LA, Martin JW, Funa K et al.: Markedly decreased expression of Class I histocompatibility antigens, proteins and in RNA in human small cell lung cancer. J Exp Med, in press.
Banks-Schlegel SP, Gazdar AF and Harris CC: Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res 45:1187, 1985.
Gazdar AF: ‘The Biology of Endocrine Tumors of the Lung’. In: The Endocrine Lung in Health and Disease, Becker KL and Gazdar AF (eds.), WB Saunders Co, Philadelphia, p 448, 1984.
Abe K, Kameya T, Yamaguchi K et al.: ‘Hormone-Producing Lung Cancers. Endocrinologie and Morphologic Studies’. In: The Endocrine Lung in Health and Disease, Becker KL and Gazdar AF (eds.), WB Saunders Co, Philadelphia, p 549, 1984.
Weisenthal LM, Marsden JA, Dill Pl et al.: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43:749, 1983.
Ihde DC, Oie H, Russel EK et al.: Feasibility of in vitro growth and chemosensitivity testing of small cell lung cancer cells in a prospective clinical trial. Proc AACR 26:369, 1985.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Ruckdeschel, J.C., Oie, H.K., Gazdar, A.F. (1986). In Vitro Characterization of Non-Small Cell Lung Cancer. In: Hansen, H.H. (eds) Lung Cancer: Basic and Clinical Aspects. Cancer Treatment and Research, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2295-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2295-5_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9414-6
Online ISBN: 978-1-4613-2295-5
eBook Packages: Springer Book Archive